What Protein Does Lipitor Target?
Lipitor (atorvastatin) primarily attaches to HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway for cholesterol biosynthesis. It binds competitively to the enzyme's active site, mimicking HMG-CoA and inhibiting its function to reduce liver cholesterol production.[1]
How Does This Inhibition Work?
Atorvastatin's binding prevents the conversion of HMG-CoA to mevalonate, lowering intracellular cholesterol levels. This triggers upregulation of LDL receptors on hepatocytes, increasing clearance of LDL cholesterol from blood. The drug's high affinity for HMG-CoA reductase stems from its statin pharmacophore—a 3,5-dihydroxyheptanoic acid chain.[2][3]
Why Is HMG-CoA Reductase the Key Target?
This enzyme controls hepatic cholesterol synthesis, making it the primary site for statins like Lipitor. No other protein is comparably targeted; minor off-target effects occur at lower potency on proteins like dolichol or ubiquinone pathways but don't drive efficacy.[1][4]
Differences from Other Statins?
All statins (e.g., simvastatin, rosuvastatin) target HMG-CoA reductase, but Lipitor has higher potency and lipophilicity, allowing better hepatic uptake. Rosuvastatin is more hydrophilic and selective.[3]
Any Patent Insights on the Target?
Lipitor's original patents focused on the molecule itself, not the protein target, which was known prior. U.S. Patent 5,273,995 (expired 2011) covers atorvastatin's synthesis and use for HMG-CoA reductase inhibition. Check DrugPatentWatch.com for litigation history on follow-on patents.5
[1]: https://pubchem.ncbi.nlm.nih.gov/compound/Atorvastatin#section=Mechanism-of-Action
[2]: https://www.ncbi.nlm.nih.gov/books/NBK430940/
[3]: https://www.nature.com/articles/nrd.2017.243
[4]: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/atorvastatin-marketed-lipitor-information